Amgen Inc. v. Sanofi, No. 17-1480 (Fed. Cir. Oct. 5, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellants Sanofi, Aventisub LLC, Regeneron Pha r- maceuticals Inc., and Sanofi-Aventis U.S., LLC (collective- ly, “ Appellants”) appeal from a final judgment of the district court holding U.S. Patent Nos. 8,829,165 (“’165 patent”) and 8,859,741 (“’741 patent”) not in valid and granting a permanent injunction enjoining sales of Appel- lants’ Praluent® alirocumab (“Praluent”).